Viking Therapeutics, Inc. Form 3/A

May 06, 2015

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

**SECURITIES** Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person \*

Lian Brian

(Last)

50

(First)

C/O VIKING THERAPEUTICS,

TORREY PINES ROAD, SUITE

(Street)

INC., Â 11119 NORTH

(Middle)

Statement

(Month/Day/Year)

04/28/2015

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Viking Therapeutics, Inc. [VKTX]

4. Relationship of Reporting

Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

04/28/2015

(Check all applicable)

(give title below) (specify below) President & CEO

\_X\_ Director 10% Owner \_X\_ Officer Other

6. Individual or Joint/Group Filing(Check Applicable Line)

\_X\_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

SAN DIEGO, CAÂ 92037

(City) (State) (Zip)

1. Title of Security (Instr. 4)

Table I - Non-Derivative Securities Beneficially Owned

2. Amount of Securities Beneficially Owned

(Instr. 4)

Ownership Form:

Direct (D) or Indirect (I) (Instr. 5)

4. Nature of Indirect Beneficial

Ownership

(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

**Expiration Date** (Month/Day/Year)

2. Date Exercisable and 3. Title and Amount of Securities Underlying Derivative Security

(Instr. 4)

4. Conversion or Exercise

5. Ownership Form of Derivative

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Price of Derivative Security:

### Edgar Filing: Viking Therapeutics, Inc. - Form 3/A

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Convertible Note due 2015	(1)	(1)	Common Stock	0 (1)	\$ <u>(1)</u>	D	Â
Convertible Note due 2015	(1)	(1)	Common Stock	0 (1)	\$ <u>(1)</u>	D	Â

## **Reporting Owners**

Reporting Owner Name / Address	Relationships				
1	Director	10% Owner	Officer	Other	
Lian Brian					
C/O VIKING THERAPEUTICS, INC.	$\hat{\Delta}$ $\mathbf{Y}$	$\hat{\Delta}$	President & CEO	$\hat{\Delta}$	
11119 NORTH TORREY PINES ROAD, SUITE 50	11 11	7 1	71 Tresident & CLO	<i>1</i> <b>1</b>	
SAN DIEGO, CA 92037					

# **Signatures**

/s/ Brian Lian,
Ph.D.

\*\*Signature of Reporting Person

Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The outstanding principal balance under the convertible note, plus all accrued and unpaid interest thereon, automatically converts into (1) shares of common stock upon the closing of a qualified initial public offering of the Issuer at a conversion price equal to 75% of the price at which shares are sold to the public. The convertible note has no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2